Insmed Incorporated (NASDAQ:INSM – Get Free Report) insider Michael Alexander Smith sold 27,871 shares of Insmed stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the completion of the transaction, the insider now owns 67,856 shares in the company, valued at approximately $5,045,093.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Insmed Stock Down 1.9 %
Shares of Insmed stock opened at $73.23 on Tuesday. The firm has a market cap of $10.88 billion, a price-to-earnings ratio of -14.00 and a beta of 1.11. The stock has a 50-day simple moving average of $74.72 and a 200-day simple moving average of $50.92. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53.
Insmed (NASDAQ:INSM – Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The business had revenue of $90.34 million for the quarter, compared to analysts’ expectations of $87.95 million. During the same period in the previous year, the business earned ($1.78) EPS. The firm’s revenue was up 17.0% on a year-over-year basis. On average, equities research analysts expect that Insmed Incorporated will post -5.42 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
View Our Latest Stock Report on INSM
Hedge Funds Weigh In On Insmed
Hedge funds have recently bought and sold shares of the business. EntryPoint Capital LLC bought a new stake in shares of Insmed during the 1st quarter worth about $33,000. Fidelis Capital Partners LLC acquired a new position in Insmed during the first quarter valued at approximately $34,000. First Horizon Advisors Inc. grew its holdings in Insmed by 83.4% during the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 287 shares during the last quarter. Headlands Technologies LLC bought a new position in shares of Insmed in the first quarter valued at approximately $59,000. Finally, CWM LLC lifted its stake in shares of Insmed by 11.0% in the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 155 shares during the last quarter.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Recommended Stories
- Five stocks we like better than Insmed
- What Does a Stock Split Mean?
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- What is the Dogs of the Dow Strategy? Overview and Examples
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- How to Read Stock Charts for Beginners
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.